Ractigen Therapeutics completes trial enrolment for ALS drug
Ractigen Therapeutics completed patient enrolment and initial dosing across all cohort groups in its Phase II clinical trial evaluating RAG 17 for ALS treatment
We haven't written up this one. Vietnam Investment Review has the full story — the link below goes straight to it.
